Edwards announced that the FDA has issued the company approval to introduce its latest transcatheter aortic heart valve, the SAPIEN 3, including the Commander Delivery System, to the U.S. market. The device was designed to lower the chances of leakage around the valve, which should reduce various side-effects, including the potential for stroke.
